BMS’ Cobenfy shows encouraging signs in Phase III Alzheimer’s psychosis studies
Bristol Myers Squibb’s (BMS) next-generation antipsychotic therapy, Cobenfy (xanomeline and trospium chloride), has been shown to trigger improvements in hallucinations…
Bristol Myers Squibb’s (BMS) next-generation antipsychotic therapy, Cobenfy (xanomeline and trospium chloride), has been shown to trigger improvements in hallucinations…
Biogen has reported two-year data from its Phase II CELIA trial showing that diranersen (BIIB080) slowed clinical decline in early…
While Priavoid’s oral Alzheimer’s disease drug has been shown to be safe and tolerable, it failed to have a significant…
ONL Therapeutics has concluded patient enrolment in its global Phase II GALAXY clinical trial assessing xelafaslatide for geographic atrophy (GA)…
Nuvation Bio has reported updated long-term follow-up findings from the Phase II J201 trial assessing safusidenib in patients with chemotherapy-…
Lipocine has dosed the first patient in a Phase III trial assessing LPCN 1154 (oral brexanolone) for the treatment of…
Teva Pharmaceuticals has announced plans to halt a Phase II clinical trial evaluating emrusolmin (TEV-'286) to treat adults with multiple…
Shanghai Zhimeng Biopharma has completed patient enrolment in the pivotal Phase II/III clinical trial of its investigational potassium-channel opener, CB03-154,…
Rapport Therapeutics’ Phase II bipolar mania study has met its primary endpoint, as it hopes to compete on the market…
Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy being developed for Alzheimer’s disease has been shown to reduce tau in a…